RESEARCH IN ENGLAND

Explore clinical trials with England locations

Search 2,970 registered studies with identifiable England locations in our dated ClinicalTrials.gov snapshot. Explore the study and local recruitment details before contacting the research team.

Condition, study or locationRecorded care areaStatus at an England locationClear filters

194 matching studies · ordered by study identifier.

The area filter uses exact source postcodes. Locations without a matched postcode remain in the England-wide results.

NCT05107674 · Interventional

A Study of NX-1607 in Adults With Advanced Malignancies

Ovarian Cancer, Epithelial · Gastric Cancer · GastroEsophageal Junction (GEJ) Cancer · Head and Neck Squamous Cell Carcinoma · Metastatic or Unresectable Melanoma · Non-small Cell Lung Cancer (NSCLC) · Metastatic Castration-resistant Prostate Cancer (mCRPC) · Malignant Pleural Mesothelioma (MPM) · Triple Negative Breast Cancer (TNBC) · Metastatic Urothelial Carcinoma · Cervical Cancer · Diffuse Large B Cell Lymphoma (DLBCL) · Richter Transformation · Microsatellite Stable Colorectal Carcinoma

Study overall: Recruiting · source record updated 9 September 2025.

6 England locations · 5 explicitly recorded as recruiting.

NCT05118555 · Observational

Evaluation of New Magnetic Resonance Techniques

Magnetic Resonance Imaging

Study overall: Recruiting · source record updated 29 November 2021.

1 England locations · 1 explicitly recorded as recruiting.

NCT05131022 · Interventional

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Diffuse Large B Cell Lymphoma (DLBCL) · Follicular Lymphoma (FL) · Mantle Cell Lymphoma (MCL) · Marginal Zone Lymphoma (MZL) · Waldenstrom Macroglobulinemia (WM) · Primary Central Nervous System Lymphoma (PCNSL) · Secondary Central Nervous System Lymphoma (SCNSL)

Study overall: Recruiting · source record updated 2 July 2026.

9 England locations · 9 explicitly recorded as recruiting.

NCT05160584 · Observational

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Study overall: Recruiting · source record updated 28 August 2026.

7 England locations · 0 explicitly recorded as recruiting.

NCT05208762 · Interventional

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of the Head and Neck · Esophageal Squamous Cell Carcinoma · Triple Negative Breast Neoplasms · Gastric Cancer · Endometrial Cancer · Pancreatic Adenocarcinoma · Hepatocellular Carcinoma

Study overall: Recruiting · source record updated 22 July 2026.

7 England locations · 7 explicitly recorded as recruiting.

NCT05253651 · Interventional

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Colorectal Neoplasms

Study overall: Recruiting · source record updated 22 July 2026.

10 England locations · 10 explicitly recorded as recruiting.

NCT05272709 · Interventional

TT-702 in Patients With Advanced Solid Tumours.

Advanced Solid Tumors

Study overall: Recruiting · source record updated 12 August 2026.

3 England locations · 3 explicitly recorded as recruiting.

NCT05307705 · Interventional

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Breast Cancer

Study overall: Recruiting · source record updated 8 September 2026.

2 England locations · 1 explicitly recorded as recruiting.

NCT05384626 · Interventional

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Locally Advanced Solid Tumor · Metastatic Solid Tumor

Study overall: Recruiting · source record updated 27 May 2026.

3 England locations · 3 explicitly recorded as recruiting.

NCT05471856 · Interventional

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Study overall: Recruiting · source record updated 4 August 2026.

3 England locations · 3 explicitly recorded as recruiting.

NCT05549297 · Interventional

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Advanced Melanoma

Study overall: Recruiting · source record updated 25 February 2026.

9 England locations · 9 explicitly recorded as recruiting.

NCT05580562 · Interventional

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

H3 K27M · Glioma

Study overall: Recruiting · source record updated 16 April 2026.

10 England locations · 10 explicitly recorded as recruiting.

NCT05652335 · Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma · Previously Treated Amyloid Light-chain (AL) Amyloidosis

Study overall: Recruiting · source record updated 28 August 2026.

2 England locations · 2 explicitly recorded as recruiting.

NCT05658640 · Interventional

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Study overall: Recruiting · source record updated 16 September 2025.

5 England locations · 0 explicitly recorded as recruiting.

NCT05709496 · Interventional

Dose De-escalation in Prostate Radiotherapy Using the MRL

Prostate Adenocarcinoma

Study overall: Recruiting · source record updated 19 April 2024.

1 England locations · 1 explicitly recorded as recruiting.

NCT05722886 · Interventional

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Haematological Malignancy · Solid Tumour

Study overall: Recruiting · source record updated 1 July 2026.

21 England locations · 20 explicitly recorded as recruiting.

NCT05745714 · Interventional

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Study overall: Recruiting · source record updated 16 September 2025.

4 England locations · 0 explicitly recorded as recruiting.

NCT05751044 · Interventional

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Study overall: Recruiting · source record updated 16 September 2025.

4 England locations · 0 explicitly recorded as recruiting.

NCT05770037 · Interventional

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type · Neoplasms by Site · Cancer · Anaplastic Large Cell Lymphoma · Lymphoma · Renal Cell Carcinoma · Neuroblastoma · Solid Tumour

Study overall: Recruiting · source record updated 24 November 2025.

21 England locations · 19 explicitly recorded as recruiting.

NCT05770102 · Interventional

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type · Neoplasms by Site · Cancer · Colorectal Neoplasms · Endometrial Neoplasms · Melanoma · Solid Tumours

Study overall: Recruiting · source record updated 24 November 2025.

21 England locations · 19 explicitly recorded as recruiting.

More ways to explore research

This is a selected international registry feed, not every study taking place in England. NIHR also lists participation opportunities, including studies that may not appear in this selection.

NIHR Be Part of Research Search the original register

Source: ClinicalTrials.gov, a United States Government database. Contains OS data © Crown copyright and database right 2026. Contains National Statistics data © Crown copyright and database right 2024; ONS country boundaries (December 2024).

Source processed: 2026-09-10 09:00:04 UTC. Retrieved: 10 September 2026. ClinicalTrials.gov terms.

How we selected and connected these records

Selected registered studies with an overall status of Recruiting or Not yet recruiting and at least one England location established by postcode, recorded nation, or source coordinates within the ONS December 2024 boundary. Retained structured fields; omitted descriptions, eligibility text, contacts and non-England locations. Deduplicated identical locations. Linked local care areas only by exact postcode geography. Location points are used for nation filtering, not directions or facility matching.